Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration.

Published

Journal Article

PURPOSE: To determine bioactivity and duration of effect of intravitreal aflibercept injection (also known as vascular endothelial growth factor Trap-Eye) for neovascular age-related macular degeneration (AMD). METHODS: In this double-masked, phase 1 study, 28 patients with lesions ≤12 disc areas, ≥50% active choroidal neovascularization (CNV), and best corrected visual acuity (BCVA) ≤20/40 were randomized 1:1 to a single intravitreal injection of aflibercept 0.15 or 4 mg. The primary end point was the change from baseline in central retinal/lesion thickness (CR/LT) at week-8. Secondary outcomes were the change from baseline BCVA, the change in CNV lesion size and area of leakage, and proportion of patients requiring repeat injection at 8 weeks. RESULTS: Mean percent decrease in CR/LT for the 4-mg and 0.15-mg groups was, respectively, 34.2 versus 13.3 at week 4 (P=0.0065), 23.8 versus 5.9 at week 6 (P=0.0380), and 25.2% versus 11.3% at week 8 (P=0.150). The 4-mg group gained a mean of 4.5 letters in BCVA (6/14 patients gaining ≥10 letters) versus 1.1 letters in 0.15-mg group (1/14 gaining ≥10 letters) at week 8. Fewer patients needed retreatment in the 4-mg group at week 8. No serious adverse event or ocular inflammation was reported in either group. CONCLUSIONS: Intravitreal aflibercept 4 mg had a safety profile similar to that of the very low dose 0.15 mg, and was well-tolerated. The 4-mg dose significantly reduced foveal thickening at weeks 4 and 6, significantly improved BCVA at weeks 6, and reduced the need for repeat injection after 8 weeks compared with intravitreal aflibercept 0.15 mg in neovascular AMD patients.

Full Text

Duke Authors

Cited Authors

  • Nguyen, QD; Campochiaro, PA; Shah, SM; Browning, DJ; Hudson, HL; Sonkin, PL; Hariprasad, SM; Kaiser, PK; Slakter, J; Haller, JA; Do, DV; Mieler, W; Chu, K; Ingerman, A; Vitti, R; Berliner, AJ; Cedarbaum, J; Clear-It 1 Investigators,

Published Date

  • December 2012

Published In

Volume / Issue

  • 28 / 6

Start / End Page

  • 581 - 588

PubMed ID

  • 22775078

Pubmed Central ID

  • 22775078

Electronic International Standard Serial Number (EISSN)

  • 1557-7732

Digital Object Identifier (DOI)

  • 10.1089/jop.2011.0261

Language

  • eng

Conference Location

  • United States